| __timestamp | Amphastar Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 106352000 |
| Thursday, January 1, 2015 | 174172000 | 144969000 |
| Friday, January 1, 2016 | 150976000 | 162364000 |
| Sunday, January 1, 2017 | 149380000 | 188462000 |
| Monday, January 1, 2018 | 187681000 | 210850000 |
| Tuesday, January 1, 2019 | 190434000 | 240515000 |
| Wednesday, January 1, 2020 | 206506000 | 255497000 |
| Friday, January 1, 2021 | 238029000 | 298182000 |
| Saturday, January 1, 2022 | 250127000 | 349103000 |
| Sunday, January 1, 2023 | 293274000 | 366887000 |
| Monday, January 1, 2024 | 389335000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the annual cost of revenue trends for Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bio-Techne consistently outpaced Amphastar, with a notable 245% increase in cost of revenue, peaking at approximately $389 million in 2023. Amphastar, while showing a steady rise, reached its highest cost of revenue at around $293 million in 2023, marking an 84% increase since 2014. The data highlights Bio-Techne's aggressive growth strategy, reflected in its higher cost base. However, the absence of 2024 data for Amphastar suggests potential volatility or strategic shifts. Investors should consider these trends when evaluating the financial health and strategic direction of these biotech giants.
Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue: Key Insights for Merck & Co., Inc. and Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for BeiGene, Ltd. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Comparison: Bio-Techne Corporation vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Mesoblast Limited
Cost of Revenue: Key Insights for Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Exelixis, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Amphastar Pharmaceuticals, Inc.
CRISPR Therapeutics AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored